Gifford Lorenz
Pulmonary Disease · Savannah, GANPI 1912076944
Payments from drug & device makers
Across 353 payments — averaging $57.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$13K
- GSK$1K
- AstraZeneca$1K
- Grifols USA, LLC$981
- Mallinckrodt Hospital Products Inc.$372
- Merck$275
- plus $3K from 33 others
What the payments were for
- Consulting fees$2,70013%
- Speaking & faculty fees$8,55042%
- Travel & lodging$1,3787%
- Food & beverage$7,37336%
- Education$2921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 29 | $13,424 |
| GSK | 75 | $1,467 |
| AstraZeneca | 53 | $1,191 |
| Grifols USA, LLC | 46 | $981 |
| Mallinckrodt Hospital Products Inc. | 9 | $372 |
| Merck | 13 | $275 |
| Regeneron Healthcare Solutions, Inc. | 12 | $273 |
| Electromed, Inc. | 22 | $252 |
| Actelion Pharmaceuticals US, Inc. | 8 | $235 |
| Jazz Pharmaceuticals Inc. | 11 | $230 |
| Inspire Medical Systems, Inc. | 2 | $156 |
| Harmony Biosciences LLC | 8 | $139 |
| La Jolla Pharmaceutical Company | 2 | $130 |
| Sunovion Pharmaceuticals Inc. | 7 | $105 |
| Sanofi | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $82 |
| Genentech USA, Inc. | 5 | $78 |
| Amgen | 4 | $71 |
| Boehringer Ingelheim | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| Optinose US, Inc. | 4 | $57 |
| Pfizer | 3 | $56 |
| Shionogi Inc | 2 | $42 |
| Portola Pharmaceuticals, LLC | 2 | $39 |
| Philips North America LLC | 2 | $39 |
| Johnson & Johnson | 3 | $39 |
| Novartis | 2 | $38 |
| AbbVie(2 entities) | 2 | $31 |
| Boston Scientific | 1 | $30 |
| Eisai Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$11,178
- Inspire Upper Airway Stimulation System$131
- Prolastin-C$124
- TRELEGY ELLIPTA$122
- NUCALA$121
- BREZTRI$120
- GIAPREZA$117
- STEGLATRO$112
- TEZSPIRE$112
- ACTHAR$100
How this compares
$20,293 in reported general payments places this provider in the 80th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Savannah
- Lawrence McDermottSavannah$963K
- Michael MullinsSavannah$132K
- Michael PerkinsSavannah$67K
- Ryan MoodySavannah$50K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.